(12) **Translation of European patent specification**

(11) **NO/EP 3145488 B1**

(19) NO

NORWAY

(51) Int Cl.
A61K 9/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.11.09
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.07.22
(86)	European Application Nr.	15723695.1
(86)	European Filing Date	2015.05.15
(87)	The European Application's Publication Date	2017.03.29
(30)	Priority	2014.05.23, EP, 14169755
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Fresenius Kabi Deutschland GmbH, Else-Kröner-Strasse 1, 61352 Bad Homburg v.d.H., Tyskland
(72)	Inventor	RINALDI, Gianluca, Via Silvestrini 9, I-00015 Monterotondo (RM), Italia FRATARCANGELI, Silvia, C.so Risorgimento 3, I-03024 Ceprano (FR), Italia DEL RIO, Alessandra, Via Ildebrando Vivanti 108, I-00144 Roma, Italia
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **LIQUID PHARMACEUTICAL COMPOSITION**

(56) References Cited:

WO-A1-2013/164837
WO-A2-2009/073569
WO-A2-2011/104381
US-A1- 2004 033 228
US-A1- 2010 137 213
US-A1- 2010 278 822
ZHENG J Y ET AL: "Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 308, no. 1-2, 3 February 2006 (2006-02-03), pages 46-51, XP027972782, ISSN: 0378-5173 [retrieved on 2006-02-03]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. En flytende farmasøytisk sammensetning bestående av:

- 50 mg/ml adalimumab;

- et sitratbuffersystem;

- en sukkerstabilisator;

- en tonisitetsmiddel;

- et overflateaktivt middel; og

- vann (for injeksjon);

- hvor nevnte adalimumab, sitratbuffersystem, sukkerstabilisator, tonisitetsmiddel og overflateaktivt middel er til stede i et molforhold på 1:14-40:288-865:28-576:0,1-3,2.